Assignee
CELLDEX THERAPEUTICS INC
US·23 granted patents·36 pending applications·64 citations·filing 2001–2024
Top patents by PatentIndex Score
59 records- 0195US10781267B2Methods of treating by administering anti-kit antibodiesCELLDEX THERAPEUTICS INC·Filed 2018·Granted Sep 22, 2020·7 cites·22 claims
- 0294US10633444B2Agonistic antibodies that bind CD40CELLDEX THERAPEUTICS INC·Filed 2019·Granted Apr 28, 2020·12 cites·8 claims
- 0392US10184007B2Methods of treating a kit-associated cancer by administering anti-kit antibodiesCELLDEX THERAPEUTICS INC·Filed 2017·Granted Jan 22, 2019·9 cites·20 claims
- 0490US11332537B2Anti-CD27 and anti-PD-L1 antibodies and bispecific constructsCELLDEX THERAPEUTICS INC·Filed 2021·Granted May 17, 2022·1 cites·26 claims
- 0590US10941201B2Methods of inducing or enhancing an immune response comprising administering agonistic anti-CD40 antibodiesCELLDEX THERAPEUTICS INC·Filed 2020·Granted Mar 9, 2021·2 cites·17 claims
- 0689US10793639B2Methods of treating by administering anti-kit antibodiesCELLDEX THERAPEUTICS INC·Filed 2018·Granted Oct 6, 2020·3 cites·22 claims
- 0789US10189907B2Polynucleotides encoding anti-KIT antibodiesCELLDEX THERAPEUTICS INC·Filed 2016·Granted Jan 29, 2019·6 cites·34 claims
- 0887US2024150493A1Anti-kit antibodies and uses thereofCELLDEX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0986US11891452B2Anti-kit antibodies and uses thereofCELLDEX THERAPEUTICS INC·Filed 2020·Granted Feb 6, 2024·1 cites·20 claims
- 1086US10774146B2Treatment of eosinophil or mast cell related disordersCELLDEX THERAPEUTICS INC·Filed 2019·Granted Sep 15, 2020·2 cites·7 claims
- 1186US2025115663A1Agonistic antibodies that bind cd40CELLDEX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1285US11180566B2Antibodies that bind human CD27 and uses thereofCELLDEX THERAPEUTICS INC·Filed 2015·Granted Nov 23, 2021·4 cites·7 claims
- 1385US2024141063A1Anti-kit antibodies and uses thereofCELLDEX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1485US2025346671A1Anti-pd-l1 antibodies and methods of use thereofCELLDEX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1584US2024287180A1Treatment of eosinophil or mast cell related disordersCELLDEX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1682US10865244B2Nucleic acids encoding agonistic antibodies that bind CD40CELLDEX THERAPEUTICS INC·Filed 2017·Granted Dec 15, 2020·1 cites·11 claims
- 1781US8362214B2Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)CELLDEX THERAPEUTICS INC·Filed 2009·Granted Jan 29, 2013·3 cites·11 claims
- 1881US7563876B2Human monoclonal antibodies to dendritic cellsCELLDEX THERAPEUTICS INC·Filed 2001·Granted Jul 21, 2009·11 cites·1 claims
- 1977US9649357B2Treatment of chronic nephropathies using soluble complement receptor type I (sCR1)CELLDEX THERAPEUTICS INC·Filed 2016·Granted May 16, 2017·2 cites·8 claims
- 2076US2022324990A1Anti-cd27 and anti-pd-l1 antibodies and bispecific constructsCELLDEX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2175US2025059291A1Cd27 agonistsCELLDEX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2273US11884699B2Anti-KIT antibodies and uses thereofCELLDEX THERAPEUTICS INC·Filed 2020·Granted Jan 30, 2024·0 cites·20 claims
- 2372US11987626B2Treatment of eosinophil or mast cell related disordersCELLDEX THERAPEUTICS INC·Filed 2020·Granted May 21, 2024·0 cites·7 claims
- 2471US11459393B2Anti-CD27 and anti-PD-L1 antibodies and bispecific constructsCELLDEX THERAPEUTICS INC·Filed 2019·Granted Oct 4, 2022·0 cites·7 claims
- 2571US2021147538A1Agonistic antibodies that bind cd40CELLDEX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2670US2022227877A1Antibodies that bind human cd27 and uses thereofCELLDEX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2766US2014314780A1Compositions Using Antibodies Directed to GPNMB and Uses ThereofCELLDEX THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 2866US2011053863A1Methods of using flt3-ligand in the treatment of cancerCELLDEX THERAPEUTICS INC·Filed 2009·Application pending·0 cites
- 2966US2026055193A1Anti-kit antibody formulations and methodsCELLDEX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3064US12297266B2Agonistic antibodies that bind human CD40 and uses thereofCELLDEX THERAPEUTICS INC·Filed 2017·Granted May 13, 2025·0 cites·19 claims
- 3163US7316812B2Cells expressing anti-Fc receptor binding componentsCELLDEX THERAPEUTICS INC·Filed 2004·Granted Jan 8, 2008·0 cites·25 claims
- 3262US11884734B2Anti-MET antibodies and methods of use thereofCELLDEX THERAPEUTICS INC·Filed 2020·Granted Jan 30, 2024·0 cites·16 claims
- 3361US2024409639A1Anti-ilt4 and anti-pd-1 bispecific constructsCELLDEX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3461US2018043014A1Compositions Using Antibodies Directed to GPNMB and Uses ThereofCELLDEX THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3560US9624300B2Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)CELLDEX THERAPEUTICS INC·Filed 2012·Granted Apr 18, 2017·0 cites·5 claims
- 3659US2024417459A1Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereofCELLDEX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3759US2024117057A1Anti-kit antibodies and uses thereofCELLDEX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3856US2024109961A1Treatment of chronic prurigoCELLDEX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3955US2015044212A1Antibodies Directed to GPNMB and Uses ThereofCELLDEX THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 4055US2022016168A1Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapyCELLDEX THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4154US2018362443A1Uses of anti-her3 antibodies for treating cancerCELLDEX THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4253US2019151351A1Regulators of anaplastic lymphoma kinase and uses thereofCELLDEX THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4353US2016355593A1Antibody vaccine conjugates and uses thereforCELLDEX THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 4451US2021077832A1Methods of treating cancer with dendritic cell mobilizing agentsCELLDEX THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4550US2017218067A1Antibodies Against T Cell Immunoglobulin Domain and Mucin Domain 1 (TIM-1) Antigen and Uses ThereofCELLDEX THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4650US2016024192A1Molecular conjugates comprising human monoclonal antibodies to dendritic cellsCELLDEX THERAPEUTICS INC·Filed 2015·Application pending·0 cites
- 4749US2015232948A1Method of Detecting and Treating Tuberous Sclerosis Complex Associated DisordersCELLDEX THERAPEUTICS INC·Filed 2015·Application pending·0 cites
- 4848US2018057595A1Anti-MET Antibodies and Methods of Use ThereofCELLDEX THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 4948US2018044429A1Cd27 agonistsCELLDEX THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 5048US2022177593A1Anti-axl antibodies and methods of use thereofCELLDEX THERAPEUTICS INC·Filed 2020·Application pending·0 cites
Showing the top 50 of 59 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when CELLDEX THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →